Aldosterone Antagonism in Chronic Kidney Disease
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Angiotensin-converting enzyme (ACE) inhibitors are potent members of the arsenal to treat chronic kidney disease (CKD). By reducing blood pressure (BP) and disproportionately decreasing intraglomerular pressure, this class of drugs also reduces proteinuria and slows progression of CKD (1,2). Given the high prevalence of cardiovascular disease in this population, it is noteworthy that ACE inhibitors also decrease the incidence of stroke, myocardial infarction (MI), and cardiovascular mortality in patients who are at high cardiovascular risk (3). More recently, data reporting similar benefits of angiotensin receptor blockers (ARB) support their use in the treatment of CKD as well, especially in individuals with type 2 diabetes (4). Furthermore, one sizable study suggested that the combination of an ACE inhibitor and ARB may be more effective than either agent alone (5). Parving and colleagues (6) called attention to the effects of high-dose ARB therapy, up to three times the recommended dose, as an additional means of effectively interrupting the renin-angiotensin-aldosterone system (RAAS). By logical extension, further blockade of the RAAS by direct antagonism of aldosterone also may prove beneficial. Indeed, aldosterone seems to be a potent effector of renal injury (7–9). In the rare cases of primary aldosteronism and its functional analogue, the even more rare Liddle’s syndrome, the observed renal injury probably is independent of the more proximal elements of the RAAS (10,11). Animal models provide an expeditious tool for assessing pathophysiologic change and the efficacy of intervention. The classic model of primary aldosteronism, the mineralocorticoid–nephrectomy–high-salt model of hypertension, develops systemic and glomerular capillary hypertension and sustains renal damage (12). In the remnant kidney model of CKD, ACE inhibitors and ARB attenuate renal injury (13). However, this protection, which is associated with suppression of aldosterone secretion, is abrogated by exogenous aldosterone infusion with return of hypertension, proteinuria, and nephrosclerosis. These results support a direct role for the mineralocorticoid in promoting renal disease. In the stroke-prone spontaneously hypertensive rat, the mineralocorticoid receptor blocker spironolactone reduces proteinuria and nephrosclerosis independent of any effect on BP or volume status (14,15). Other animal models, including radiation nephritis (16), cyclosporine toxicity (17), diabetes (18), obstruction (19), and other models of hypertension (20,21), implicate aldosterone in the pathogenesis of progressive kidney disease. Most of these studies of experimental disease implicate aldosterone by virtue of the benefits of the mineralocorticoid receptor antagonists spironolactone and eplerenone. Human studies are of limited scope and also have focused on the effects of these receptor blockers but tend to corroborate the major role of aldosterone in renal injury. Mechanisms of Aldosterone Action Blood Pressure and Sodium and Potassium Balance Sodium and potassium balance are strongly influenced by aldosterone. Aldosterone controls sodium reabsorption in the distal nephron through regulation of the epithelial sodium channel (ENaC). In turn, aldosterone acts as a key determinant of volume status and thereby BP. Patients with primary aldosteronism are characterized by volume expansion and hypertension. A similar phenotype is observed in patients with Liddle’s syndrome, in whom mutations in ENaC cause its constitutive activity. Even in people with primary hypertension, aldosterone often seems to play a role. Indeed, subjects in the Framingham Offspring cohort who had higher serum aldosterone levels but within the normal range were at increased risk for developing hypertension (22). Aldosterone directly and indirectly influences ENaC expression (Figure 1). In the classic model of steroid hormone action, aldosterone binds to a cytoplasmic mineralocorticoid receptor. This complex translocates to the nucleus, which results in increased transcription of target genes such as ENaC subunits (23). Another genomic target of aldosterone is serum- and glucocorticoid-regulated kinase 1 (Sgk1). This enzyme is under transcriptional control by aldosterone (24,25) and is responsible for phosphorylating and thereby inhibiting Nedd4-2, a regulatory protein that promotes ENaC degradation (26,27). Therefore, aldosterone regulates sodium reabsorption by controlling ENaC trafficking as well. Increases in plasma K+ increase aldosterone secretion (28). The mineralocorticoid also has been shown to increase expression of the renal outer medullary potassium channel, which enhances K+ secretion (29). This effect is synergistic with sodium reabsorption; the latter allows for an increase in luminal negativity in the renal tubules and thereby facilitates K+ secretion. Aldosterone also acts through Sgk1 to amplify this effect. Sgk1 seems to work in concert with the Na+/H+ exchange regulat
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Phosphorylation of Nedd4‐2 by Sgk1 regulates epithelial Na+ channel cell surface expression
Debonneville, C., Flores, S. Y., Kamynina, E., Plant, P. J., Tauxe, C., Thomas, M. A., Münster, C., Chraïbi, A., Pratt, J. H., Horisberger, J., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.7052 · Cited by 711 · cited 1×
“for phosphorylating and thereby inhibiting Nedd4-2, a regulatory protein that promotes ENaC degradation (26,27).”
BackgroundEffectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466
Cited by
The incidence and implications of aldosterone breakthrough
Bomback, A. S., & Klemmer, P. J. (2007) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0575 · Cited by 420
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388
Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
Lazich, I., & Bakris, G. L. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.008 · Cited by 164
Hassan, M., Qureshi, W., Sroujieh, L. S., Albashaireh, D., BouMalham, S., Liroff, M., Amjad, W., Khalid, F., Hadid, H., & Alirhayim, Z. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320314539180 · Cited by 15
Metadata
- Authors
- Ponda, M. P., & Hostetter, T. H.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2006-07
- Volume
- 1
- Issue
- 4
- Pages
- 668-677
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2086158964
- Cited by
- 75
- References
- 3
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aldosterone Antagonism in Chronic Kidney Disease. https://app.cochat.ai/papers/10.2215/cjn.00120106
- The paper
- Ponda, M. P., & Hostetter, T. H. (2006). Aldosterone Antagonism in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.00120106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.